Page 1

10X GENOMICS 10x Genomics Reports Third Quarter 2021 Financial Results Q3 2021 revenue growth of 74 % over prior year and 8 % over prior quarter PLEASANTON , Calif . November 3 , 2021 _ 10x Genomics , Inc. ( Nasdaq : TXG ) today reported financial results for the third quarter ended September 30 , 2021 . Recent Highlights • • Revenue was $ 125.3 million for the third quarter , representing a 74 % increase over the corresponding period of 2020 and an 8 % increase compared to the second quarter of 2021 . Began shipping the Chromium X instrument , providing flexible analysis of up to one million cells per experiment , and high - throughput Gene Expression and Immune Profiling consumables , enabling affordable and routine large - scale gene expression and multiomic analyses . Continued the strong momentum of customer publications by surpassing 3,000 research papers using our products , advancing scientific discovery in application areas such as oncology , immunology , neuroscience and infectious disease . " Our team delivered strong results this quarter , successfully launching the Chromium X while navigating the complexities of this operating environment , " said Serge Saxonov , Co - founder and CEO of 10x Genomics . " Our conviction in the vast opportunity ahead remains as strong as ever , and we will accelerate our investments to continue to innovate , drive scale and fulfill the promise of single cell and spatial biology . " Third Quarter 2021 Financial Results Revenue was $ 125.3 million for the three months ended September 30 , 2021 , a 74 % increase from $ 71.8 million for the three months ended September 30 , 2020. This increase was primarily the result of increased consumables revenue driven by growth in the instrument installed base . Gross margin was 80 % for the third quarter of 2021 , which is flat as compared to 80 % for the corresponding prior year period as lower accrued royalties related to the Bio - Rad litigation were offset by the impact in shifting product mix . Operating expenses were $ 116.7 million for the third quarter of 2021 , a 5 % decrease from $ 122.7 million for the three months ended September 30 , 2020. This decrease was driven by lower in - process research and development expense this quarter due to the $ 40.6 million charge during the quarter ended September 30 , 2020 related to the acquisition of CartaNA and decreased legal expenses . This decrease was partially offset by increased operating expenses related to higher personnel expenses , including stock - based compensation , increased expenses related to facilities and technology and increased marketing expenses . Operating loss was $ 15.9 million for the third quarter of 2021 , as compared to $ 65.3 million for the corresponding prior year period which included $ 40.6 million of in - process research and development expense related to the acquisition of CartaNA . Operating loss includes $ 26.0 million of stock - based compensation for the third quarter of 2021 , as compared to $ 13.8 million for the third quarter of 2020 . Net loss was $ 17.2 million for the third quarter of 2021 , as compared to a net loss of $ 65.8 million for the corresponding prior year period . Cash and cash equivalents were $ 600.4 million as of September 30 , 2021 . 1